Chalmers, J. R. and Simpson, E. and Apfelbacher, C. J. and Thomas, K. S. and von Kobyletzki, L. and Schmitt, J. and Singh, J. A. and Svensson, A. and Williams, H. C. and Abuabara, K. and Aoki, V. and Ardeleanu, M. and Awici-Rasmussen, M. and Barbarot, S. and Berents, T. L. and Block, J. and Bragg, A. and Burton, T. and Clemmensen, K. K. Bjerring and Creswell-Melville, A. and Dinesen, M. and Drucker, A. and Eckert, L. and Flohr, C. and Garg, M. and Gerbens, L. A. A. and Graff, A. L. B. and Hanifin, J. and Heinl, D. and Humphreys, R. and Ishii, H. A. and Kataoka, Y. and Leshem, Y. A. and Marquort, B. and Massuel, M. -A. and Merhand, S. and Mizutani, H. and Murota, H. and Murrell, D. F. and Nakahara, T. and Nasr, I. and Nograles, K. and Ohya, Y. and Osterloh, I. and Pander, J. and Prinsen, C. and Purkins, L. and Ridd, M. and Sach, T. and Schuttelaar, M. -L. A. and Shindo, S. and Smirnova, J. and Sulzer, A. and Gjerde, E. Synnove and Takaoka, R. and Talmo, H. Vestby and Tauber, M. and Torchet, F. and Volke, A. and Wahlgren, C. -F. and Weidinger, S. and Weisshaar, E. and Wollenberg, A. and Yamaga, K. and Zhao, C. Y. and Spuls, P. I. (2016) Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). BRITISH JOURNAL OF DERMATOLOGY, 175 (1). pp. 69-79. ISSN 0007-0963, 1365-2133
Full text not available from this repository.Abstract
This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmo, Sweden on 23-24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [ including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MEASUREMENT INSTRUMENTS; ECZEMA; QUALITY; DELPHI; COSMIN; SIGNS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Institut für Epidemiologie und Präventivmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 02 Apr 2019 12:46 |
| Last Modified: | 02 Apr 2019 12:46 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3653 |
Actions (login required)
 |
View Item |
